Ivabradine, a novel heart rate slower: Is it a sword of double blades in patients with idiopathic dilated cardiomyopathy?;Ivabradin, yeni bir kalp hızı yavaşlatıcısı: İdiyopatik dilate kardiyomiyopatili hastalarda iki tarafı keskin bir kılıç mıdır?

Anadolu Kardiyoloji Dergisi

Volumn 11, Issue 5, 2011, Pages 402-406

  Rayan, Mona ^a   Tawfik, Mazen ^a   Alabd, Ali ^a   Gamal, Amr ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Dilated cardiomyopathy; Efficacy; Heart failure; Ivabradine; Safety

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IVABRADINE; SPIRONOLACTONE;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HOLTER MONITORING; HUMAN; MALE; OPEN STUDY; PHOTOPSIA; PR INTERVAL; PROSPECTIVE STUDY; QRS COMPLEX; QT INTERVAL; VISUAL DISORDER;

EID: 79960529483     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2011.110     Document Type: Article

References (13)

1. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823-30.
2. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27: 65-75.
3. Gullestad L, Wikstrand J, Deedwania P, Hjelmarson A, Eqstrup K, Elkayam U, et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 2005; 45: 252-9.
4. Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006; 12: 10-38.
5. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.
6. Ferrari R, Rapezzi C, Lombardi F. The revival of heart rate. Eur Heart J 1999; 20: 853-4.
7. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109: 1674-9.
8. Ciobotaru V, Heimburger M, Louedec L, Heymes C, Ventura-Clapier R, Bedossa P, et al. Effect of long-term heart rate reduction by I(f) current inhibition on pressure overload-induced heart failure in rats. J Pharmacol Exp Ther 2008; 324: 43-9.
9. Logeart D, Gueffet J, Rouzet F, Pousset F, Chavelas C, Solal AC, et al. Heart rate per se impacts cardiac function in patients with systolic heart failure and pacing: a pilot study. Eur J Heart Fail 2009; 11: 53-7.
10. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-36.
11. Sharpe N, Doughty RN. Left ventricular remodelling and improved long-term outcomes in chronic heart failure. Eur Heart J 1998; 19: 36-9.
12. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101: 865-9.
13. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-16.